

Special Situations for COVID-19 Vaccination of Children and Adolescents

Age Transitions and Interchangeability



Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage **based on their age on the day of vaccination**.

- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 5 to age 6 years




Recommended: Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:

Dose 1 (Age 5):

0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border)



4–8 weeks



Child turns 6

Dose 2 (Age 6):

0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)



Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

Either dose may be:

- 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)


Dose 1: Age 5



OR



4–8 weeks



Dose 2: Age 6



OR



Special Situations for COVID-19 Vaccination of Children and Adolescents

Age Transitions and Interchangeability



Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (continued)

Children who turn from age 11 years to 12 years



Recommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

Dose 1 (Age 11):
0.50 mL (50 mcg)
of the product
authorized for
children ages
6–11 years (dark
blue cap/purple
label border)



Dose 2 (Age 12):
0.50 mL (100 mcg)
of the product
authorized for
children ages
12 years and
older (red cap/light
blue label border)



Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.
Either dose may be:

- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border),
OR
- 0.50 mL (100 mcg) of the product authorized for children ages 12–17 years (red cap/light blue label border)

Dose 1: Age 11



OR



4-8 weeks



Dose 2: Age 12



OR



Special Situations for COVID-19 Vaccination of Children and Adolescents

Age Transitions and Interchangeability



Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage **based on their age on the day of vaccination**.

- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 4 to age 5 years



Recommended: Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2 in the primary series should receive:

Dose 1 (Age 4):
0.20 mL (3 mcg)
of the product
authorized for
children ages 6
months–4 years
(maroon cap and
label border)



3–8 weeks



Child turns 5

Dose 2 (Age 5):
0.20 mL (10 mcg)
of the product
authorized for
children ages 5–11
years (orange cap
and label border)



8 weeks

Dose 3 (Age 5):
0.20 mL (10 mcg)
of the product
authorized for
children ages
5–11 years
(orange cap and
label border)



Recommended: Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3 in the primary series should receive:

Dose 1 (Age 4):
0.20 mL (3 mcg)
of the product
authorized for
children ages 6
months–4 years
(maroon cap and
label border)



3–8 weeks

Dose 2 (Age 4):
0.20 mL (3 mcg)
of the product
authorized for
children ages 6
months–4 years
(maroon cap and
label border)



8 weeks



Child turns 5

Dose 3 (Age 5):
0.20 mL (10 mcg)
of the product
authorized for
children ages
5–11 years
(orange cap and
label border)



Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

- A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border)

Dose 1: Age 4



3–8 weeks

Dose 2: Age 4 or 5



Special Situations for COVID-19 Vaccination of Children and Adolescents

Age Transitions and Interchangeability



Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (Continued)

OR

- A 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border). Each of doses 2 and 3 may be with the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border), or the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border).

Dose 1: Age 4



3-8 weeks



Dose 2: Age 4 or 5



OR



8 weeks



Dose 3: Age 5



OR



Children who turn from age 11 years to 12 years



Recommended: Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

Dose 1 (Age 11):

0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)




3-8 weeks



Child turns 12

Dose 2 (Age 12):

0.30 mL (30 mcg) of the product authorized for children ages 12–17 years (gray cap and label border)



Acceptable: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:

- 0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border), or
- 0.30 mL (30 mcg) of the product authorized for children ages 12–17 years (gray cap and label border)

Dose 1: Age 11



OR



3-8 weeks



Dose 2: Age 12



OR



Special Situations for COVID-19 Vaccination of Children and Adolescents

Age Transitions and Interchangeability



Interchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines

COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is given, count both doses if the recommended interval between doses has been met.
 - If ages 6 months through 4 years, complete the series following the Pfizer-BioNTech 3-dose schedule using an age-appropriate vaccine from either manufacturer. See examples.
 - Repeating doses is not recommended.
- This guidance applies to:
 - All eligible children, including those who are moderately or severely immunocompromised.
 - Vaccines from both manufacturers, regardless which vaccine was given first.

Examples:

Vaccination history: 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.

